Sai Life Sciences LimitedSAILIFECorporate

Healthcare Diagnostics & Research Latest results: Mar 2026 10 quarters of data

₹1,389.40

MCap ₹29,510 Cr · P/E 86.0

Sai Life Sciences Limited — Stock analysis & AI research Sai Life Sciences Limited — Multibagger AI analysis Sai Life Sciences Limited — Seasonality — best & worst months Sai Life Sciences Limited — Technical indicators & charts Sai Life Sciences Limited — Technical setup — score, trend, support & resistance Sai Life Sciences Limited — Live exchange announcements

📋 High ROCE Stocks 📋 High Operating Margin Stocks 📋 High Interest Coverage Stocks 📋 Low Debt Stocks 📋 Small Cap Stocks List 📈 20-Day Breakdown Stocks 🏭 Pharma sector

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹602 Cr

Sales · Mar 2026

+3.8% YoY

₹177 Cr

Operating Profit · Mar 2026

+12.0% YoY

29.4%

OPM % · Mar 2026

+8.1% YoY

₹104 Cr

Net Profit · Mar 2026

+18.2% YoY

₹4.92

EPS · Mar 2026

+16.0% YoY

📝 Sai Life Sciences Limited — results explained

Quarter ended March 2026 (Q4 FY26)

Sai Life Sciences Limited reported revenue of ₹602 crore for the quarter ended March 2026 (Q4 FY26), up 3.8% from ₹580 crore in the same quarter last year, and up 8.3% sequentially over the December 2025 quarter.

Net profit rose 18.2% year-on-year to ₹104 crore, from ₹88 crore. Earnings per share (EPS) came in at ₹4.92.

Operating profit stood at ₹177 crore — an operating margin (OPM) of 29.4%, compared with 27.2% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Sai Life Sciences Limited posted revenue of ₹2,181 crore, a growth of 29.4% over FY25, with a net profit of ₹343 crore (up 105.3% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹2,181 crore with a net profit of ₹343 crore.

Valuation snapshot

At the current price of ₹1,389.40, SAILIFE has a market capitalisation of ₹29,510 crore and a trailing P/E of about 86.0.

Within the Diagnostics & Research industry, it is the largest of the 3 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 34.50%, foreign institutional investors (FIIs) 19.91%, domestic institutional investors (DIIs) 32.32%, public shareholders 13.26% of Sai Life Sciences Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹29,510 Cr

Current Price ?

₹1,389.4

P/E ?

86.05above ind

Industry P/E ?

70.20

P/B ?

11.88

P/S ?

13.53

P/FCF ?

-355.54

Enterprise Value ?

₹29,798 Cr

EV/EBITDA ?

47.15

PEG ?

0.38

Earnings Yield ?

1.6%

Dividend Yield ?

0.00%

Profitability & Returns

Sales (TTM) ?

₹2,181 Cr

OPM ?

29.0%

Profit after tax (TTM) ?

₹343 Cr

EPS (TTM) ?

₹16.15

ROCE ?

20.0%

ROE ?

13.8%

ROA ?

9.5%

Growth

Sales — latest qtr ?

₹602 Cr

PAT — latest qtr ?

₹104 Cr

YoY qtr sales growth ?

3.8%

YoY qtr profit growth ?

18.2%

Sales growth (3y) ?

22%

Sales growth (5y) ?

24%

Profit growth (3y) ?

226%

Profit growth (5y) ?

42%

Financial Health

Debt ?

₹288 Cr

Debt to Equity ?

0.12

Interest Coverage ?

11.9

Current Ratio ?

N/A

Ownership

Promoter holding ?

34.50%

Change in promoter holding ?

-0.65%

Pledged percentage ?

N/A

Market

Return 3 months ?

9.2%

Return 6 months ?

43.1%

🗓️ Quarterly results (10 quarters · ₹ Cr)

same fiscal quarter as Mar bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	YoY %	QoQ %
Sales	384	439	280	396	429	580	496	527	556	602	+3.8%	+8.3%
Operating Profit	96	125	26	102	111	158	121	146	188	177	+12.0%	-5.9%
Other Income	11	3	8	10	9	10	10	15	0	16	+60.0%	—
Interest	23	21	21	21	22	11	12	9	10	8	-27.3%	-20.0%
Depreciation	31	31	31	36	31	37	38	40	44	45	+21.6%	+2.3%
Profit Before Tax	53	76	-18	55	68	119	78	111	130	139	+16.8%	+6.5%
Net Profit	40	56	-14	42	51	88	58	83	98	104	+18.2%	+6.5%
EPS	—	—	—	—	2.74	4.24	2.90	4.00	4.75	4.92	+16.0%	+3.6%
OPM %	25.0%	28.5%	9.3%	25.8%	25.9%	27.2%	24.4%	27.7%	33.8%	29.4%	+8.1%	-13.0%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric	FY25	FY26	TTM	YoY %
Sales	₹1,685 Cr	₹2,181 Cr	₹2,181 Cr	+29.4%
Operating Profit	₹397 Cr	₹632 Cr	₹632 Cr	+59.1%
OPM %	23.58%	28.98%	28.98%	+22.9%
NPM %	9.92%	15.73%	15.73%	+58.6%
Other Income	₹37 Cr	₹41 Cr	₹41 Cr	+9.5%
Depreciation	₹135 Cr	₹167 Cr	₹167 Cr	+23.6%
Interest	₹75 Cr	₹39 Cr	₹39 Cr	-47.8%
EBIT	₹262 Cr	₹465 Cr	₹465 Cr	+77.4%
PBT	₹224 Cr	₹458 Cr	₹458 Cr	+104.7%
Tax	₹17 Cr	—	—	—
Net Profit	₹167 Cr	₹343 Cr	₹343 Cr	+105.3%
EPS	₹6.98	₹16.57	₹16.57	+137.4%
Material Cost	₹117 Cr	—	—	—
Employee Cost	₹121 Cr	—	—	—
Extraordinary Items	—	₹8 Cr	₹8 Cr	—

🏛️ Balance Sheet (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Equity Capital	18	18	21	21	+0.0%
Reserves	870	957	2,108	2,463	+16.8%
Borrowings	933	928	352	288	-18.2%
Other Liabilities	358	359	665	854	+28.4%
Total Liabilities	2,179	2,262	3,146	3,626	+15.3%
Fixed Assets	1,037	1,180	1,488	1,815	+22.0%
CWIP	151	107	124	270	+117.7%
Investments	2	2	2	50	+2400.0%
Other Assets	989	973	1,531	1,490	-2.7%
Total Assets	2,179	2,262	3,146	3,626	+15.3%

💧 Cash Flow (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Cash from Operating Activity	219	263	314	509	+62.1%
Cash from Investing Activity	-99	-191	-536	-395	+26.3%
Cash from Financing Activity	-201	-95	301	-124	-141.2%
Net Cash Flow	-80	-24	79	-10	-112.7%
Free Cash Flow	148	82	-55	-83	-50.9%
CFO/OP	132%	96%	82%	87%	+6.1%

➗ Ratios (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Debtor Days	85	64	76	62	-18.4%
Inventory Days	121	72	93	97	+4.3%
Days Payable	180	113	253	182	-28.1%
Cash Conversion Cycle	25	22	-83	-24	+71.1%
Working Capital Days	36	12	66	78	+18.2%
ROCE %	6%	11%	14%	20%	+42.9%

👥 Shareholding (latest 6 periods)

Metric	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026	% Chg
Promoters	35.15%	34.95%	34.70%	34.61%	34.53%	34.50%	-0.1%
FIIs	14.57%	22.50%	21.41%	21.17%	19.65%	19.91%	+1.3%
DIIs	21.64%	29.92%	31.41%	31.54%	32.71%	32.32%	-1.2%
Public	28.64%	12.65%	12.49%	12.69%	13.11%	13.26%	+1.1%
No. of Shareholders	1,26,380	1,19,705	1,14,820	1,17,527	1,25,096	1,43,124	+14.4%

⚖️ Peer comparison

Industry: Diagnostics & Research · 3 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	SAILIFE SAI LIFE	₹1,585.00	33,664	95.7	2,181	343	29.0%	15.7%	29.4%	105.3%	3.8%	18.2%
2	LALPATHLAB Dr. Lal	₹1,897.00	31,676	58.5	2,892	546	29.0%	18.9%	12.3%	3.4%	19.1%	27.2%
3	SYNGENE Syngene International	₹383.10	15,420	69.8	3,600	221	22.3%	6.1%	2.6%	-36.2%	-15.8%	-110.4%

❓ Frequently asked questions

What was Sai Life Sciences Limited's revenue in Q4 FY26?

What was Sai Life Sciences Limited's net profit in Q4 FY26?